Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
A Phase II, Pharmacokinetic (PK), Pharmacodynamic (PD) and Biological Correlative Study of the Efficacy and Safety of Dual Antiangiogenic Inhibition Using Bevacizumab and Sorafenib in Patients With Advanced Malignant Melanoma
Status: Enrolling
Updated:  10/19/2017
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio
mi
from
San Antonio, TX
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
A Phase II, Pharmacokinetic (PK), Pharmacodynamic (PD) and Biological Correlative Study of the Efficacy and Safety of Dual Antiangiogenic Inhibition Using Bevacizumab and Sorafenib in Patients With Advanced Malignant Melanoma
Status: Enrolling
Updated: 10/19/2017
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Family Lifestyle Actions and Risk Education Study
FLARE: Family Lifestyle Actions and Risk Education Study for Children With a Familial Risk for Melanoma
Status: Enrolling
Updated:  10/24/2017
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Family Lifestyle Actions and Risk Education Study
FLARE: Family Lifestyle Actions and Risk Education Study for Children With a Familial Risk for Melanoma
Status: Enrolling
Updated: 10/24/2017
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Status: Enrolling
Updated:  10/24/2017
Kaiser Foundation Research Institute
mi
from
Oakland, CA
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Status: Enrolling
Updated: 10/24/2017
Kaiser Foundation Research Institute
mi
from
Oakland, CA
Click here to add this to my saved trials
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Status: Enrolling
Updated:  10/24/2017
University of Colorado Denver
mi
from
Aurora, CO
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Status: Enrolling
Updated: 10/24/2017
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques
Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques
Status: Enrolling
Updated:  10/26/2017
UF Health
mi
from
Gainesville, FL
Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques
Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques
Status: Enrolling
Updated: 10/26/2017
UF Health
mi
from
Gainesville, FL
Click here to add this to my saved trials
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
Phase II Study of CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
Status: Enrolling
Updated:  10/31/2017
New York University Langone Clinical Cancer Center
mi
from
New York, NY
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
Phase II Study of CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
Status: Enrolling
Updated: 10/31/2017
New York University Langone Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage
Topical Imiquimod 5% Cream in the Treatment of Nodular Basal Cell Carcinoma After Initial Treatment With Curettage
Status: Enrolling
Updated:  11/1/2017
Wake Forest University Medical Center
mi
from
Winston-Salem, NC
Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage
Topical Imiquimod 5% Cream in the Treatment of Nodular Basal Cell Carcinoma After Initial Treatment With Curettage
Status: Enrolling
Updated: 11/1/2017
Wake Forest University Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients
Adjuvant Interleukin2 (Proleukin)and 5-(3,3 Dimethyl-1-Triazeno) Imidazole-4-Carboxamide (DTIC) in Resected High-Risk Primary and Regionally Metastatic Melanoma
Status: Enrolling
Updated:  11/3/2017
James Graham Brown Cancer Center
mi
from
Louisville, KY
Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients
Adjuvant Interleukin2 (Proleukin)and 5-(3,3 Dimethyl-1-Triazeno) Imidazole-4-Carboxamide (DTIC) in Resected High-Risk Primary and Regionally Metastatic Melanoma
Status: Enrolling
Updated: 11/3/2017
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
A Pilot Study to Investigate the Off Label Use of Vismodegib as an Adjuvant to Surgery for Basal Cell Carcinoma Tumors (BCCs)
Status: Enrolling
Updated:  11/6/2017
Stanford University
mi
from
Stanford, CA
Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
A Pilot Study to Investigate the Off Label Use of Vismodegib as an Adjuvant to Surgery for Basal Cell Carcinoma Tumors (BCCs)
Status: Enrolling
Updated: 11/6/2017
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Boston, MA
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Boston, MA
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
New York, NY
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Nashville, TN
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Houston, TX
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
San Francisco, CA
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  11/10/2017
GSK Investigational Site
mi
from
Saint Louis, MO
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 11/10/2017
GSK Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women
Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women
Status: Enrolling
Updated:  11/15/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women
Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women
Status: Enrolling
Updated: 11/15/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections
Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute S. Aureus Skin and Skin Structure Infections in Patients With Comorbid Conditions: A Randomized Trial
Status: Enrolling
Updated:  11/16/2017
Grady Memorial Hospital
mi
from
Atlanta, GA
Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections
Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute S. Aureus Skin and Skin Structure Infections in Patients With Comorbid Conditions: A Randomized Trial
Status: Enrolling
Updated: 11/16/2017
Grady Memorial Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections
Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute S. Aureus Skin and Skin Structure Infections in Patients With Comorbid Conditions: A Randomized Trial
Status: Enrolling
Updated:  11/16/2017
University of Chicago Medical Center
mi
from
Chicago, IL
Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections
Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute S. Aureus Skin and Skin Structure Infections in Patients With Comorbid Conditions: A Randomized Trial
Status: Enrolling
Updated: 11/16/2017
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
Kaiser Permanente Medical Center
mi
from
Riverside, CA
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
Kaiser Permanente Medical Center
mi
from
Riverside, CA
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
Lakeland Regional Cancer Center
mi
from
Lakeland, FL
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
Lakeland Regional Cancer Center
mi
from
Lakeland, FL
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
Northwestern University
mi
from
Chicago, IL
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
Rush University Medical Center
mi
from
Chicago, IL
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
Advocate Lutheran General Hospital
mi
from
Park Ridge, IL
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
Advocate Lutheran General Hospital
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
Iu Health Goshen Center For Cancer Care
mi
from
Goshen, IN
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
Iu Health Goshen Center For Cancer Care
mi
from
Goshen, IN
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
James Graham Brown Cancer Center, University of Louisville
mi
from
Louisville, KY
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
James Graham Brown Cancer Center, University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
National Institutes of Health
mi
from
Bethesda, MD
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
National Institutes of Health
mi
from
Bethesda, MD
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
Carolinas Medical Center
mi
from
Charlotte, NC
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
The Christ Hospital
mi
from
Cincinnati, OH
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
The Christ Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
Saint Luke's University Hospital-Bethlehem Campus
mi
from
Bethlehem, PA
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
Saint Luke's University Hospital-Bethlehem Campus
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
M D Anderson Cancer Center
mi
from
Houston, TX
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  11/16/2017
Aurora Saint Lukes Medical Center
mi
from
Milwaukee, WI
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 11/16/2017
Aurora Saint Lukes Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma
Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Stage I and II Malignant Melanoma
Status: Enrolling
Updated:  11/20/2017
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma
Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Stage I and II Malignant Melanoma
Status: Enrolling
Updated: 11/20/2017
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)
An Open Label Study Employing the Topical Immunomodulator Diphenylcyclopropenone in a Stabilized Gel to Treat Cutaneous Metastases
Status: Enrolling
Updated:  11/27/2017
Rockefeller University
mi
from
New York, NY
Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)
An Open Label Study Employing the Topical Immunomodulator Diphenylcyclopropenone in a Stabilized Gel to Treat Cutaneous Metastases
Status: Enrolling
Updated: 11/27/2017
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma
Status: Enrolling
Updated:  11/30/2017
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma
Status: Enrolling
Updated: 11/30/2017
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma
Status: Enrolling
Updated:  11/30/2017
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma
Status: Enrolling
Updated: 11/30/2017
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma
A Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen (LMI) Vaccine for the Treatment of Stage IV Melanoma
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma
A Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen (LMI) Vaccine for the Treatment of Stage IV Melanoma
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma
Neoadjuvant Anti-CTLA4 Blockade With Ipilimumab in Patients With AJCC Stage IIIB-C (Tx,1-4, N1b,2b, 2c, 3, M0) Melanoma: Immunogenicity And Biomarker Analysis
Status: Enrolling
Updated:  12/5/2017
University of Pittsburgh Medical Center/University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma
Neoadjuvant Anti-CTLA4 Blockade With Ipilimumab in Patients With AJCC Stage IIIB-C (Tx,1-4, N1b,2b, 2c, 3, M0) Melanoma: Immunogenicity And Biomarker Analysis
Status: Enrolling
Updated: 12/5/2017
University of Pittsburgh Medical Center/University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Birmingham, AL
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Tucson, AZ
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
San Francisco, CA
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Miami Beach, FL
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Orlando, FL
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials